Health
BioNTech Beats Expectations, Gives Update on Cancer Drugs
BioNTech’s earnings per diluted share were €0.81 ($0.88) in the third quarter, according to a statement Monday.
Photographer: Cyril Marcilhacy/BloombergThis article is for subscribers only.
BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines.
Mainz, Germany-based BioNTech posted earnings of €0.81 ($0.88) per diluted share in the period, according to a statement Monday. Analysts surveyed by Bloomberg expected a loss of €1.84.